OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
CONNYSE67

Concentra Group Holdings Parent, Inc.

Healthcare Facilities & ServicesVerified

Concentra Group Holdings Parent, Inc. has a liquidity position that is considered high, with a current ratio of 1.14, which is close to the minimum comfort range. The company's liquidity is further strained by a negative net cash position after subtracting total debt. The company's liquidity is supported by $79.9 million in cash and equivalents, but this is significantly less than its long-term debt of $1.56 billion. In terms of profitability, Concentra's return on equity (ROE) is 42.31%, which is a strong indicator of the company's ability to generate profits from shareholders' equity. However, its return on assets (ROA) is 5.82%, which is relatively modest. The company's debt-to-equity ratio is 3.98, indicating a high level of leverage. This suggests that the company is using a significant amount of debt to finance its operations, which could increase its financial risk. Concentra's business is divided into three segments: Occupational Health Centers, Onsite Health Clinics, and Other Businesses. The Occupational Health Centers segment is the largest, with a broad geographic presence across 41 states. The Onsite Health Clinics segment operates in 44 states, and the Other Businesses segment includes services such as telemedicine and pharmacy. The company's revenue is concentrated in the United States, with no significant international operations. The company's growth trajectory is expected to be influenced by its capital expenditures and operating cash flow. The company's capital expenditures for FY2025 were $82.3 million, and its operating cash flow was $279.4 million. The company's free cash flow was $197.1 million, which is a positive sign for its ability to fund future growth. The company's revenue for FY2025 was $2.16 billion, and its operating income was $334.0 million. The company faces several risk factors, including liquidity risk due to its high debt-to-equity ratio and the potential for dilution. The company has a medium dilution risk, with source documents mentioning dilution or offering risk. The company's liquidity risk is also a concern, as its current ratio is close to the minimum comfort range. The company's credit risk is not explicitly mentioned, but its high leverage could impact its credit rating. Recent events include the company's initial public offering (IPO) and the special stock distribution of 104,093,503 shares of the company's common stock to Select's stockholders. The company also financed transactions using a combination of new debt financing, available borrowing capacity, and cash on hand. The company's financial statements show a net income attributable to the company and non-controlling interests, as well as distributions and redemption value adjustments.

30-day price · CON+4.32 (+19.9%)
Low$20.20High$26.66Close$26.02As of19 May, 00:00 UTC
Profile
CompanyConcentra Group Holdings Parent, Inc.
ExchangeNYSE
TickerCON
CIK0002014596
SICServices-Specialty Outpatient Facilities, NEC
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Concentra Group Holdings Parent, Inc. provides occupational health services in the United States, operating through occupational health centers, onsite health clinics, and complementary services such as telemedicine, pharmacy, and medical compliance administration.

Classification. Concentra is classified under the Healthcare sector, specifically in the Healthcare Services & Equipment business sector and the Healthcare Facilities & Services industry, with a confidence level of 0.92.

Concentra Group Holdings Parent, Inc. has a liquidity position that is considered high, with a current ratio of 1.14, which is close to the minimum comfort range. The company's liquidity is further strained by a negative net cash position after subtracting total debt. The company's liquidity is supported by $79.9 million in cash and equivalents, but this is significantly less than its long-term debt of $1.56 billion. In terms of profitability, Concentra's return on equity (ROE) is 42.31%, which is a strong indicator of the company's ability to generate profits from shareholders' equity. However, its return on assets (ROA) is 5.82%, which is relatively modest. The company's debt-to-equity ratio is 3.98, indicating a high level of leverage. This suggests that the company is using a significant amount of debt to finance its operations, which could increase its financial risk. Concentra's business is divided into three segments: Occupational Health Centers, Onsite Health Clinics, and Other Businesses. The Occupational Health Centers segment is the largest, with a broad geographic presence across 41 states. The Onsite Health Clinics segment operates in 44 states, and the Other Businesses segment includes services such as telemedicine and pharmacy. The company's revenue is concentrated in the United States, with no significant international operations. The company's growth trajectory is expected to be influenced by its capital expenditures and operating cash flow. The company's capital expenditures for FY2025 were $82.3 million, and its operating cash flow was $279.4 million. The company's free cash flow was $197.1 million, which is a positive sign for its ability to fund future growth. The company's revenue for FY2025 was $2.16 billion, and its operating income was $334.0 million. The company faces several risk factors, including liquidity risk due to its high debt-to-equity ratio and the potential for dilution. The company has a medium dilution risk, with source documents mentioning dilution or offering risk. The company's liquidity risk is also a concern, as its current ratio is close to the minimum comfort range. The company's credit risk is not explicitly mentioned, but its high leverage could impact its credit rating. Recent events include the company's initial public offering (IPO) and the special stock distribution of 104,093,503 shares of the company's common stock to Select's stockholders. The company also financed transactions using a combination of new debt financing, available borrowing capacity, and cash on hand. The company's financial statements show a net income attributable to the company and non-controlling interests, as well as distributions and redemption value adjustments.
Key takeaways
  • Concentra has a high liquidity risk due to its current ratio being close to the minimum comfort range and a negative net cash position after subtracting total debt.
  • The company's return on equity is strong at 42.31%, but its return on assets is relatively modest at 5.82%.
  • Concentra's business is concentrated in the United States, with no significant international operations.
  • The company's growth is supported by a positive free cash flow of $197.1 million and a revenue of $2.16 billion for FY2025.
  • The company faces medium dilution risk, with source documents mentioning dilution or offering risk.
  • Recent events include the company's IPO and the special stock distribution of shares to Select's stockholders.
  • --
  • # RATIONALES
Financial snapshot
PeriodFY2025
CurrencyUSD
Revenue$2.16B
Gross profit
Operating income$334.0M
Net income$166.4M
R&D
SG&A$203.3M
D&A
SBC$10.5M
Operating cash flow$279.4M
CapEx$82.3M
Free cash flow$197.1M
Total assets$2.86B
Total liabilities$2.44B
Total equity$393.3M
Cash & equivalents$79.9M
Long-term debt$1.56B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY2025$2.16B$334.0M$166.4M$197.1M
FY2024$1.90B$304.8M$166.5M$210.3M
FY2025$1.90B$304.8M$166.5M$210.3M
FY2024$1.84B$287.6M$179.9M$169.4M
FY2025$1.84B$287.6M$179.9M$169.4M
PeriodGross %Op %Net %FCF %
FY2025
FY2024
FY2025
FY2024
FY2025
PeriodAssetsEquityCashDebt
FY2025$2.86B$393.3M$79.9M
FY2024$2.52B$275.7M$183.3M
FY2025$2.52B$275.7M$183.3M
FY2024$2.33B$1.16B$31.4M
FY2025$2.33B$1.16B
PeriodOCFCapExFCFSBC
FY2025$279.4M$82.3M$197.1M$10.5M
FY2024$274.7M$64.3M$210.3M$2.3M
FY2025$274.7M$64.3M$210.3M$2.3M
FY2024$234.3M$65.0M$169.4M$651.0k
FY2025$234.3M$65.0M$169.4M$651.0k
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
Q3 2025$1.62B$264.3M$131.7M$98.5M
Q2 2025$1.05B$169.9M$83.5M$59.1M
Q3 2025$44.6M
Q1 2025$500.8M$80.3M$38.9M-$4.0M
PeriodGross %Op %Net %FCF %
Q3 2025
Q2 2025
Q3 2025
Q1 2025
PeriodAssetsEquityCashDebt
Q3 2025$2.84B$385.5M$49.9M
Q2 2025$2.84B$342.6M$73.9M
Q3 2025$347.8M
Q1 2025$2.73B$307.1M$52.1M
PeriodOCFCapExFCFSBC
Q3 2025$160.7M$62.2M$98.5M$6.9M
Q2 2025$100.1M$41.0M$59.1M$4.6M
Q3 2025
Q1 2025$11.7M$15.7M-$4.0M$2.3M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book-$1.30B
Net cash-$1.48B
Current ratio1.1
Debt/Equity4.0
ROA5.8%
ROE42.3%
Cash conversion1.7%
CapEx/Revenue3.8%
SBC/Revenue0.5%
Asset intensity
Dilution ratio-0.3%
Risk assessment
Dilution riskMedium
Liquidity riskHigh
  • Current ratio is close to the minimum comfort range.
  • Net cash is negative after subtracting total debt.
  • Source documents mention dilution or offering risk.
Industry benchmarks
Activity: Biotechnology · cohort 9 companies
MetricCONActivity
Op margin15.4%11.5% medp25 9.9% · p75 15.0%top quartile
Net margin7.7%8.6% medp25 6.3% · p75 12.4%below median
Gross margin28.8% medp25 28.8% · p75 28.8%
CapEx / revenue3.8%4.2% medp25 3.8% · p75 4.2%below median
Debt / equity398.0%71.3% medp25 60.7% · p75 71.3%top quartile
Observations
IR observations
market data ESG controversies score100.0
market data ESG governance pillar35.6
market data ESG social pillar21.6
market data insider trading score4.0
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
SEC filingstype companyfacts · CIK 0002014596 · 250 us-gaap concepts
2026-05-01 15:47 UTC#7f2f91fd
Source: analysis-pipeline (hybrid)Generated: 2026-05-01 15:49 UTCJob: 5ec928d1